NASDAQ:OABI OmniAb (OABI) Stock Price, News & Analysis → Bible Shocker: Have You Seen Elon Musk’s Miracle? (From InvestorPlace) (Ad) Free OABI Stock Alerts $4.45 -0.10 (-2.20%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$4.43▼$4.5950-Day Range$4.43▼$5.4352-Week Range$3.78▼$6.72Volume431,279 shsAverage Volume546,540 shsMarket Capitalization$521.23 millionP/E RatioN/ADividend YieldN/APrice Target$9.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get OmniAb alerts: Email Address OmniAb MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside102.2% Upside$9.00 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment0.40Based on 10 Articles This WeekInsider TradingAcquiring Shares$1.17 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.61) to ($0.39) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.40 out of 5 starsMedical Sector520th out of 921 stocksCommercial Physical Research Industry9th out of 12 stocks 3.5 Analyst's Opinion Consensus RatingOmniAb has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageOmniAb has only been the subject of 4 research reports in the past 90 days.Read more about OmniAb's stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for OABI. Previous Next 0.0 Dividend Strength Dividend YieldOmniAb does not currently pay a dividend.Dividend GrowthOmniAb does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for OABI. Previous Next 1.9 News and Social Media Coverage News SentimentOmniAb has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for OmniAb this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for OABI on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added OmniAb to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, OmniAb insiders have bought 1,052.27% more of their company's stock than they have sold. Specifically, they have bought $1,167,750.00 in company stock and sold $101,343.00 in company stock.Percentage Held by InsidersOnly 7.00% of the stock of OmniAb is held by insiders.Percentage Held by Institutions72.08% of the stock of OmniAb is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about OmniAb's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for OmniAb are expected to grow in the coming year, from ($0.61) to ($0.39) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of OmniAb is -6.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of OmniAb is -6.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOmniAb has a P/B Ratio of 1.73. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about OmniAb's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad True Market Insidersget a piece of the profit from this land This isn’t the prettiest land on earth. But it might be the most valuable. And you don’t have to own, lease, or rent any land.Click here to see my #1 investment for 2024. About OmniAb Stock (NASDAQ:OABI)OmniAb, Inc., a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic, a bispecific rat, and OmniClic, a bispecific chicken, designed for discovery of bispecific antibody applications; OmniTaur, which provides unique structural characteristics of cow antibodies for complex targets; and OmniDeep, a suite of in silico, an AI and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.Read More OABI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OABI Stock News HeadlinesMay 16 at 7:50 PM | markets.businessinsider.comCraig-Hallum Reaffirms Their Buy Rating on OmniAb (OABI)May 16 at 4:54 AM | americanbankingnews.comOmniAb (NASDAQ:OABI) Rating Reiterated by BenchmarkMay 15, 2024 | businesswire.comOmniAb Presents High-Throughput Single B-cell Screening xPloration® Data at the 20th Annual PEGS Boston SummitMay 13, 2024 | americanbankingnews.comOmniAb, Inc. to Post Q1 2025 Earnings of ($0.15) Per Share, Leerink Partnrs Forecasts (NASDAQ:OABI)May 12, 2024 | finance.yahoo.comOmniAb, Inc. (NASDAQ:OABI) Q1 2024 Earnings Call TranscriptMay 11, 2024 | au.investing.comEarnings call: OmniAb Inc. Q1 2024 financial results and updatesMay 11, 2024 | finance.yahoo.comOmniAb First Quarter 2024 Earnings: Misses ExpectationsMay 11, 2024 | finance.yahoo.comWe're Keeping An Eye On OmniAb's (NASDAQ:OABI) Cash Burn RateMay 11, 2024 | markets.businessinsider.comTruist Financial Keeps Their Buy Rating on OmniAb (OABI)May 11, 2024 | americanbankingnews.comOmniAb (NASDAQ:OABI) Shares Gap Down Following Weak EarningsMay 9, 2024 | investorplace.comOABI Stock Earnings: OmniAb Misses EPS, Misses Revenue for Q1 2024May 9, 2024 | seekingalpha.comOmniAb, Inc. 2024 Q1 - Results - Earnings Call PresentationMay 9, 2024 | businesswire.comOmniAb Reports First Quarter 2024 Financial Results and Business HighlightsMay 1, 2024 | businesswire.comOmniAb to Participate in Five Investor Conferences in MayApril 22, 2024 | finance.yahoo.comOmniAb to Report First Quarter 2024 Financial Results on May 9April 22, 2024 | businesswire.comOmniAb to Report First Quarter 2024 Financial Results on May 9April 11, 2024 | investing.comOmniAb's chief legal officer sells shares worth over $36kApril 9, 2024 | markets.businessinsider.comRBC Capital Remains a Buy on OmniAb (OABI)March 28, 2024 | msn.comOver $1M Bet On OmniAb? Check Out These 3 Stocks Insiders Are BuyingMarch 26, 2024 | finance.yahoo.comOmniAb, Inc. (NASDAQ:OABI) Analysts Are More Bearish Than They Used To BeMarch 25, 2024 | finance.yahoo.comOmniAb Inc (OABI) President and CEO Matthew Foehr Acquires 225,000 SharesMarch 22, 2024 | markets.businessinsider.comBenchmark Co. Reaffirms Their Buy Rating on OmniAb (OABI)March 21, 2024 | markets.businessinsider.comOmniAb’s Market Potential and Financial Stability Affirm Buy RatingMarch 21, 2024 | finance.yahoo.comOmniAb, Inc. (NASDAQ:OABI) Q4 2023 Earnings Call TranscriptMarch 21, 2024 | markets.businessinsider.comOmniAb’s Strategic Growth and Resilience Reinforce Buy Rating Amidst Q4 Revenue ShortfallSee More Headlines Receive OABI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OmniAb and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today5/19/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Commercial physical research Sub-IndustryN/A Current SymbolNASDAQ:OABI CUSIPN/A CIK1846253 Webwww.omniab.com Phone510-250-7800FaxN/AEmployees106Year FoundedN/APrice Target and Rating Average Stock Price Target$9.00 High Stock Price Target$11.00 Low Stock Price Target$7.00 Potential Upside/Downside+102.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-50,620,000.00 Net Margins-301.62% Pretax Margin-374.48% Return on Equity-19.93% Return on Assets-16.65% Debt Debt-to-Equity RatioN/A Current Ratio4.38 Quick Ratio4.38 Sales & Book Value Annual Sales$34.16 million Price / Sales15.26 Cash FlowN/A Price / Cash FlowN/A Book Value$2.57 per share Price / Book1.73Miscellaneous Outstanding Shares117,130,000Free Float108,927,000Market Cap$521.23 million OptionableOptionable Beta-0.08 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Matthew W. Foehr (Age 51)President, CEO & Director Comp: $967.72kMr. Kurt A. Gustafson (Age 56)Executive VP of Finance & CFO Comp: $558.48kMr. Charles S. Berkman J.D. (Age 55)Chief Legal Officer & Secretary Comp: $734.33kMs. Cia McCaffreyVice President of People & TalentDr. Bill Harriman Ph.D.Senior Vice President of Antibody DiscoveryMs. Marie-Cecile van de Lavoir D.V.M.Ph.D., Senior Vice President of Technical Operations & GeneticsDr. Christel Iffland Ph.D.Senior Vice President of Antibody TechnologiesDr. Douglas S. Krafte Ph.D. (Age 66)Senior VP of Ion Channels/Transporters & Icagen Ion Channel Technology Site Head Ms. Donna Ventura CPASenior Vice President of Corporate ControllerMore ExecutivesKey CompetitorsAbsciNASDAQ:ABSIMaxCyteNASDAQ:MXCTKalVista PharmaceuticalsNASDAQ:KALVCabaletta BioNASDAQ:CABAApplied TherapeuticsNASDAQ:APLTView All CompetitorsInsiders & InstitutionsJanus Henderson Group PLCBought 81,541 shares on 5/16/2024Ownership: 6.710%California State Teachers Retirement SystemSold 5,371 shares on 5/16/2024Ownership: 0.075%First Sabrepoint Capital Management LPSold 76,552 shares on 5/15/2024Ownership: 1.349%Price T Rowe Associates Inc. MDBought 3,108 shares on 5/15/2024Ownership: 0.023%Bellevue Group AGBought 11,456 shares on 5/15/2024Ownership: 0.010%View All Insider TransactionsView All Institutional Transactions OABI Stock Analysis - Frequently Asked Questions Should I buy or sell OmniAb stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OmniAb in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" OABI shares. View OABI analyst ratings or view top-rated stocks. What is OmniAb's stock price target for 2024? 4 brokers have issued 1 year target prices for OmniAb's stock. Their OABI share price targets range from $7.00 to $11.00. On average, they expect the company's stock price to reach $9.00 in the next twelve months. This suggests a possible upside of 102.2% from the stock's current price. View analysts price targets for OABI or view top-rated stocks among Wall Street analysts. How have OABI shares performed in 2024? OmniAb's stock was trading at $6.17 at the beginning of 2024. Since then, OABI shares have decreased by 27.9% and is now trading at $4.45. View the best growth stocks for 2024 here. When is OmniAb's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our OABI earnings forecast. How were OmniAb's earnings last quarter? OmniAb, Inc. (NASDAQ:OABI) released its quarterly earnings results on Thursday, May, 9th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.17) by $0.02. The business had revenue of $3.80 million for the quarter, compared to analysts' expectations of $6 million. OmniAb had a negative net margin of 301.62% and a negative trailing twelve-month return on equity of 19.93%. During the same period in the prior year, the company posted ($0.06) EPS. What ETF holds OmniAb's stock? iShares Genomics Immunology and Healthcare ETF holds 161,593 shares of OABI stock, representing 0.53% of its portfolio. Who are OmniAb's major shareholders? OmniAb's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Janus Henderson Group PLC (6.71%), Vanguard Group Inc. (4.88%), William Blair Investment Management LLC (2.87%), Rice Hall James & Associates LLC (2.25%), Private Management Group Inc. (1.95%) and Villere ST Denis J & Co. LLC (1.77%). Insiders that own company stock include Jennifer R Cochran, John L Higgins, Kurt A Gustafson and Matthew W Foehr. View institutional ownership trends. How do I buy shares of OmniAb? Shares of OABI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:OABI) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaDems have chosen Biden replacement?Paradigm PressExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsPOTUS in ‘25 Not Biden/Trump, ButThe Freeport Society41 banks launch ‘crypto dollar’Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OmniAb, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
